https://www.nature.com/articles/d41586-021-01299-y Skip to main content Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement Advertisement Nature * View all journals * Search * My Account Login * Explore content * Journal information * Publish with us Subscribe * Sign up for alerts * RSS feed 1. nature 2. news 3. article NEWS 13 May 2021 Delaying a COVID vaccine's second dose boosts immune response Older people who waited 11-12 weeks for their second jab had higher peak antibody levels than did those who waited only 3 weeks. * Heidi Ledford 1. Heidi Ledford View author publications You can also search for this author in PubMed Google Scholar * Share on Twitter * Share on Facebook * Share via E-Mail An elderly man receives a dose of the Pfizer-BioNTech COVID-19 vaccine at El-Menzah sports hall in Tunisia's capital. A man in Tunis receives a dose of the Pfizer-BioNTech vaccine for COVID-19. Credit: Jdidi Wassim/SOPA Images/LightRocket via Getty You have full access to this article via your institution. Download PDF Facing a limited vaccine supply, the United Kingdom embarked on a bold public-health experiment at the end of 2020: delaying second doses of COVID-19 vaccines in a bid to maximize the number of people who would be at least partially protected from hospitalization and death. Now, a study suggests that delaying the second dose of the Pfizer-BioNTech mRNA vaccine could boost antibody responses after the second inoculation more than threefold in those older than 80. It is the first direct study of how such a delay affects coronavirus antibody levels, and could inform vaccine scheduling decisions in other countries, the authors say. "This study further supports a growing body of evidence that the approach taken in the UK for delaying that second dose has really paid off," Gayatri Amirthalingam, an epidemiologist at Public Health England in London and a co-author of the preprint, said during a press briefing. Many COVID-19 vaccines are given in two doses: the first initiates an immune response, and the second, 'booster' shot strengthens it. Clinical trials of the three vaccines used in the United Kingdom generally featured a three- to four-week gap between doses. But for some existing vaccines, a longer wait between first and second doses yields a stronger immune response. Delaying the COVID-19 booster shots could also expand partial immunity among a greater swathe of the population than could the shorter dosing schedule. On 30 December, the United Kingdom announced that it would delay the second dose by up to 12 weeks after the first. To determine whether the delay paid off, Amirthalingam and her colleagues studied 175 vaccine recipients older than 80 who received their second dose of the Pfizer vaccine either 3 weeks or 11-12 weeks after the first dose. The team measured recipients' levels of antibodies against the SARS-CoV-2 spike protein and assessed how immune cells called T cells, which can help to maintain antibody levels over time, responded to vaccination. Peak antibody levels were 3.5 times higher in those who waited 12 weeks for their booster shot than were those in people who waited only 3 weeks. Peak T-cell response was lower in those with the extended interval. But this did not cause antibody levels to decline more quickly over the nine weeks after the booster shot. The results are reassuring, but are specific to the Pfizer vaccine, which is not available in many low-to-middle income countries, says Alejandro Cravioto, chair of the World Health Organization's Strategic Advisory Group of Experts on Immunization. Countries will need to consider whether the variants that are circulating in their particular region might raise infection risk after only one vaccine dose, he says. For the United Kingdom, extending the interval between doses was clearly the right choice, but the country's lockdown deserves part of the credit for that success, says Stephen Griffin, a virologist at the University of Leeds, UK. "People are theoretically vulnerable between their first and second jab," he says. "What's worked in the UK is maintaining restrictions at the same time as vaccinating." doi: https://doi.org/10.1038/d41586-021-01299-y Latest on: Public health India's neighbours race to sequence genomes as COVID surges India's neighbours race to sequence genomes as COVID surges News 14 MAY 21 How a worrisome coronavirus variant spread unnoticed How a worrisome coronavirus variant spread unnoticed News 13 MAY 21 How the world failed to curb COVID How the world failed to curb COVID News 12 MAY 21 Vaccines Afghanistan: vaccinate drug users against COVID-19 Correspondence 11 MAY 21 Mice with severe COVID symptoms could speed vaccine effort Mice with severe COVID symptoms could speed vaccine effort News 11 MAY 21 Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses Article 10 MAY 21 Immunology India's neighbours race to sequence genomes as COVID surges India's neighbours race to sequence genomes as COVID surges News 14 MAY 21 Thymic development of gut-microbiota-specific T cells Thymic development of gut-microbiota-specific T cells Article 12 MAY 21 Fibroblast cells reveal their ancestry Fibroblast cells reveal their ancestry News & Views 12 MAY 21 Jobs from Nature Careers * + o All jobs + o Postdoc The University of Chicago (UChicago) Chicago, IL, United States JOB POST o Gene Editing Research Scientist Vertex Pharmaceuticals Incorporated Watertown, United States JOB POST o Postdoc Stanford School of Medicine Palo Alto, United States JOB POST o Postdoctoral Fellows in Structural Immunology University of Notre Dame (ND) South Bend, IN, United States JOB POST Nature Briefing An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday. Email address [ ] [ ] Yes! Sign me up to receive the daily Nature Briefing email. I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy. Sign up Related Articles * [d41586-021] Pfizer COVID vaccine protects against worrying coronavirus variants * [d41586-021] Could mixing COVID vaccines boost immune response? * [d41586-021] The race to curb the spread of COVID vaccine disinformation * [d41586-021] What it will take to vaccinate the world against COVID-19 * [d41586-021] Why Oxford's positive COVID vaccine results are puzzling scientists Subjects * Public health * Vaccines * Immunology * SARS-CoV-2 Advertisement Sign up to Nature Briefing An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday. Email address [ ] [ ] Yes! Sign me up to receive the daily Nature Briefing email. I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy. Sign up * Close Nature Briefing Sign up for the Nature Briefing newsletter -- what matters in science, free to your inbox daily. Email address [ ] Sign up [ ] I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy. Close Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing Explore content * Research articles * News * Opinion * Research Analysis * Careers * Books & Culture * Podcasts * Videos * Current issue * Browse issues * Collections * Subjects * Follow us on Facebook * Follow us on Twitter * Subscribe * Sign up for alerts * RSS feed Journal information * About the Journal * Awards * Editorial policies Publish with us * For Authors * For Referees * Submit manuscript Search Search articles by subject, keyword or author [ ] Show results from [All journals] Search Advanced search Quick links * Explore articles by subject * Find a job * Guide to authors * Editorial policies Nature ISSN 1476-4687 (online) nature.com sitemap Nature portfolio * About us * Press releases * Press office * Contact us * * * Discover content * Journals A-Z * Articles by subject * Nano * Protocol Exchange * Nature Index Publishing policies * Nature portfolio policies * Open access Author & Researcher services * Reprints & permissions * Research data * Language editing * Scientific editing * Nature Masterclasses * Nature Research Academies Libraries & institutions * Librarian service & tools * Librarian portal * Open research * Recommend to library Advertising & partnerships * Advertising * Partnerships & Services * Media kits * Branded content Career development * Nature Careers * Nature Conferences * Nature events Regional websites * Nature Africa * Nature China * Nature India * Nature Italy * Nature Japan * Nature Korea * Nature Middle East Legal & Privacy * Privacy Policy * Use of cookies * Manage cookies/Do not sell my data * Legal notice * Accessibility statement * Terms & Conditions * California Privacy Statement Springer Nature (c) 2021 Springer Nature Limited